نتائج البحث - "K. Vandormael"

1

MO01.19 An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab+Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%

المؤلفون: A. Frederickson, Balazs Halmos, C. Kalyvas, Ralph P. Insinga, Thomas Burke, Bilal Piperdi, K. Vandormael

المصدر: Journal of Thoracic Oncology. 16:S23-S24

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, biology, business.industry, First line, Ipilimumab, Pembrolizumab, Indirect comparison, PD-L1, Internal medicine, biology.protein, medicine, Nivolumab, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d2f4908bc0afa6061cf8e6050b415694
https://doi.org/10.1016/j.jtho.2020.10.067

2

MO01.18 An indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC

المؤلفون: Thomas Burke, A. Frederickson, Bilal Piperdi, K. Vandormael, Ralph P. Insinga, C. Kalyvas, Balazs Halmos

المصدر: Journal of Thoracic Oncology. 16:S23

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, biology, business.industry, First line, Ipilimumab, Pembrolizumab, Indirect comparison, Internal medicine, PD-L1, medicine, biology.protein, In patient, Nivolumab, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b2f49b91edf4b74f9a619119d6cd2c41
https://doi.org/10.1016/j.jtho.2020.10.066

3

MO01.20 Pembrolizumab+Chemo versus Atezolizumab+Chemo+/-Bevacizumab for First-Line Nonsquamous NSCLC: A Matching-Adjusted Indirect Comparison

المؤلفون: Bilal Piperdi, K. Vandormael, Thomas Burke, C. Kalyvas, Balazs Halmos, A. Frederickson

المصدر: Journal of Thoracic Oncology. 16:S24

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Matching (statistics), Bevacizumab, business.industry, First line, Pembrolizumab, Indirect comparison, Atezolizumab, Internal medicine, medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::869f6205c096af22ad680e38c12fdf2e
https://doi.org/10.1016/j.jtho.2020.10.068

4

PCN193 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

المؤلفون: K. Vandormael, A. Arunachalam, B.E. Bates, T. Harding, Ralph P. Insinga, H. Dawson

المصدر: Value in Health. 22:S473

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Cost-effectiveness analysis, Pembrolizumab, medicine.disease, Pemetrexed, Non squamous, Internal medicine, Platinum chemotherapy, medicine, Non small cell, business, Lung cancer, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ca3dacd06926ae8764cd8e0ec86d82a0
https://doi.org/10.1016/j.jval.2019.09.389

View record from ScienceDirect

Full Text via ClinicalKey

5

188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

المؤلفون: K. Vandormael, M.C. Pietanza, Rina Hui, W. Malbecq, Delvys Rodriguez-Abreu, Julie R. Brahmer, Tibor Csőszi, Martin Reck, Andrew G. Robinson

المصدر: Journal of Thoracic Oncology. 13:S112-S113

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2f41a94950b6f0f6211a6ca4edc27108
https://doi.org/10.1016/s1556-0864(18)30462-3

6

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia

المؤلفون: H. Giezek, Alice R. Mao, S. Shah, Richard Ceska, C. McCrary Sisk, J. F. Paolini, B. Gil-Extremera, K. Vandormael, Darbie Maccubbin

المصدر: International Journal of Clinical Practice. 64:727-738

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Indoles, Statin, medicine.drug_class, Atorvastatin, Hypercholesterolemia, Niacin, Gastroenterology, Young Adult, chemistry.chemical_compound, High-density lipoprotein, Double-Blind Method, Internal medicine, Humans, Medicine, cardiovascular diseases, Aged, Dyslipidemias, Hypolipidemic Agents, Aged, 80 and over, Dose-Response Relationship, Drug, Prostaglandin D2, business.industry, Cholesterol, HDL, nutritional and metabolic diseases, Cholesterol, LDL, General Medicine, Middle Aged, Drug Combinations, B vitamins, Treatment Outcome, Endocrinology, chemistry, Tolerability, Simvastatin, Delayed-Action Preparations, Female, lipids (amino acids, peptides, and proteins), Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Laropiprant, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7b573da24158755998293742982d462
https://doi.org/10.1111/j.1742-1241.2010.02370.x

7

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study

المؤلفون: K. Vandormael, Michel Farnier, Maurizio Averna, Rachid Massaad, Luc Missault, Amy O. Johnson-Levonas, Margus Viigimaa, Philippe Brudi, Helena Vaverkova

المساهمون: Farnier, M, Averna, M, Missault, L, Vaverkova, H, Viigimaa, M, Massaad, R, Vandormael, K, Johnson-Levonas, AO, Brudi, P

المصدر: International Journal of Clinical Practice. 63:547-559

مصطلحات موضوعية: Adult, Male, Simvastatin, medicine.medical_specialty, imvastatin, Statin, medicine.drug_class, Hypercholesterolemia, Coronary Artery Disease, Gastroenterology, hypercholesterolaemic, chemistry.chemical_compound, Double-Blind Method, Ezetimibe, Risk Factors, Internal medicine, medicine, Humans, Rosuvastatin, Rosuvastatin Calcium, Aged, Aged, 80 and over, Sulfonamides, biology, business.industry, Cholesterol, Cholesterol, LDL, General Medicine, Middle Aged, Fluorobenzenes, Pyrimidines, Treatment Outcome, Endocrinology, chemistry, HMG-CoA reductase, biology.protein, Azetidines, Drug Therapy, Combination, Female, lipids (amino acids, peptides, and proteins), Ezetimibe/simvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, ezetimibe, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0814858567982b0597e6c15270f747ab
https://doi.org/10.1111/j.1742-1241.2009.02022.x

8

Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event

المؤلفون: K. Vandormael, R. Massaad, Philippe Brudi, J.P. Reckless, T. Pomykaj, D.P. Henry, S.T. Lim, Amy O. Johnson-Levonas

المصدر: Cardiology. 113:89-97

مصطلحات موضوعية: Male, Simvastatin, medicine.medical_specialty, Statin, medicine.drug_class, Hypercholesterolemia, Urology, Ezetimibe, Simvastatin Drug Combination, Coronary Disease, Ezetimibe, medicine, Humans, Potency, Pharmacology (medical), In patient, Angina, Unstable, cardiovascular diseases, Aged, Apolipoproteins B, Coronary event, Dose-Response Relationship, Drug, business.industry, Anticholesteremic Agents, Cholesterol, HDL, nutritional and metabolic diseases, Middle Aged, Coronary heart disease, Drug Combinations, C-Reactive Protein, Azetidines, Female, lipids (amino acids, peptides, and proteins), Ezetimibe/simvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae5a6cd6ce609b8f549de1ed36dbcd6d
https://doi.org/10.1159/000172795

Find this article in full text from ProQuest

9

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

المؤلفون: Philippe Brudi, C Allen, Amy O. Johnson-Levonas, T. Pomykaj, K. Lis, John P. D. Reckless, R. Massaad, K. Vandormael, S.T. Lim, P. Henry

المصدر: International Journal of Clinical Practice. 62:539-554

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::03e2713954a0baf1c787a2b7e2a82327
https://doi.org/10.1111/j.1742-1241.2008.01697.x

10

Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease

المؤلفون: N. Amabile, R. Massaad, Vivencio Barrios, A. O. Johnson-Levonas, K. Vandormael, J. W. Chen, C. Allen, F. Paganelli

المصدر: International Journal of Clinical Practice. 59:1377-1386

مصطلحات موضوعية: Adult, Male, Simvastatin, medicine.medical_specialty, Apolipoprotein B, Atorvastatin, Hypercholesterolemia, Taiwan, Coronary Disease, Gastroenterology, Intestinal absorption, chemistry.chemical_compound, Double-Blind Method, Ezetimibe, Internal medicine, Humans, Medicine, Pyrroles, Aged, Apolipoproteins B, Aged, 80 and over, biology, business.industry, Cholesterol, Anticholesteremic Agents, Cholesterol, HDL, Cholesterol, LDL, General Medicine, Middle Aged, Atherosclerosis, Europe, Treatment Outcome, Endocrinology, chemistry, Heptanoic Acids, biology.protein, Azetidines, Drug Therapy, Combination, Female, lipids (amino acids, peptides, and proteins), Ezetimibe/simvastatin, business, medicine.drug, Lipoprotein

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfaabaaa89e307f7bd96741c70ed4697
https://doi.org/10.1111/j.1368-5031.2005.00714.x

تنقيح النتائج